Merck exercises option on one Kelun ADC, returns another as it tweaks broad deal
More than two years into its partnership with China’s Kelun-Biotech, Merck has made further choices on which part of the sprawling early-stage pipeline it wants to move forward. The pharma giant will...
View ArticleClik here to view.
J&J buys another medtech company, this time paying $600M upfront for...
In its fifth acquisition of the year, Johnson & Johnson is again tapping into the medical technology field, which has become a bigger part of its business. The New Jersey healthcare conglomerate...
View ArticleClik here to view.
TCGX and JPM help Pathalys raise $105M to go up against Amgen in subset of...
North Carolina biotech Pathalys Pharma expects to do a rare thing with its nine-figure Series B: file for FDA approval. Whereas most Series B financing rounds get a biotech into Phase 1 or through...
View ArticleBig employers are spending even more money on pharmacy costs, driven by...
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Pharmacy costs are taking up a bigger chunk of employers’ total healthcare spending as popular GLP-1...
View ArticleKymera seeks to raise $225M; Adcendo, Multitude's new ADC deal
Plus, news about Talus Bioscience, Moleculin, Organon and Eli Lilly: Kymera Therapeutics aims to raise $225M: The public offering will be used to fund Kymera’s pipeline, and some funds could be used...
View ArticleHouse lawmakers call on FDA to investigate clinical trials run alongside...
A group of bipartisan representatives called on the FDA to play an “active role” in ensuring the US “remains ahead” of China in biotech and urged the regulator to investigate clinical trials conducted...
View ArticleEmergent joins broader efforts for mpox vaccine drive in Africa
Certain pharma companies, governments and public health agencies have separately pledged to help build up vaccine supply in Africa to address the mpox outbreak. Emergent BioSolutions on Monday said it...
View ArticleFTC backs FDA plan to remove switching study requirement for interchangeable...
The Federal Trade Commission is backing a recent FDA proposal to officially remove the requirement that biosimilar developers must run switching studies to obtain interchangeability designations....
View ArticleLawsuit alleges Biogen schemed with PBMs to preserve Tecfidera market
A lawsuit filed against Biogen last week alleges the company participated in a kickback scheme with pharmacy benefit managers to promote its blockbuster multiple sclerosis drug Tecfidera instead of...
View ArticleClik here to view.
J&J scores approval for Rybrevant combo in first-line lung cancer, stoking...
Johnson & Johnson scored a label expansion for Rybrevant in combination with the newly-approved Lazcluze to treat certain first-line lung cancer patients, putting it in direct competition with...
View ArticleWuXi Biologics’ ADC spinout reports revenue jump despite Biosecure risk
ADCs are so hot that WuXi Biologics’ specialist company has so far appeared immune to the Biosecure threat as it unveiled a rise in revenues, manufacturing build momentum and an upsurge in workforce...
View ArticleSemaglutide may come with a higher risk of suicidal thoughts, JAMA study finds
A new observational study has found an increased risk of suicidal ideation among patients who take Novo Nordisk’s flagship weight loss drug semaglutide compared to other drugs, adding to a mixed bag of...
View ArticleClik here to view.
After Pfizer layoffs, Array chemists regather at next-gen obesity biotech...
A small piece of the multibillion-dollar restructuring at Pfizer has a light at the end of the tunnel, and it’s in Boulder, CO. Just a few months after research operations ended at the home of Array...
View ArticleAadi axes 80% of staffers as it winds down Phase 2 solid tumor trial that’s...
Not even a year since it named Dave Lennon as CEO, Aadi Bioscience is facing major headwinds as it pulls back from a series of trials of its only cancer asset and cuts a majority of its staffers. The...
View ArticleClik here to view.
Dr. Reddy's and Stanford spinout Kainomyx partner up on anti-malarial program
Dr. Reddy’s Laboratories, its CRDMO arm Aurigene and Stanford spinout Kainomyx are teaming up to develop an anti-malarial drug with a new mechanism of action. In the partnership, Kainomyx will develop...
View ArticleClik here to view.
BridgeBio forms another offshoot with $300M in commitments
BridgeBio is again offloading pieces of its pipeline as it stares down a November drug approval decision that could spark competition with Pfizer and Alnylam. The California biotech has formed a new...
View ArticleVandria raises another $10M; Nykode ends Phase 2 trial in cervical cancer
Plus, news about Retension Pharmaceuticals: Vandria tops up Series A with another $10M: The Swiss biotech increased its round total to $30.7 million after getting a new investment from the Hevolution...
View ArticleFDA rejects Regeneron’s multiple myeloma bispecific antibody over...
The FDA rejected linvoseltamab, Regeneron’s experimental antibody for multiple myeloma, the company announced Wednesday morning. In an earnings call earlier this month, Regeneron CEO Leonard Schleifer...
View ArticleClik here to view.
Indian CDMOs unlikely to see sudden surge in clients if China bill passes,...
Although CDMOs based in India continue to see an uptick in inquiries because of the Biosecure Act, executives have tempered expectations on how soon queries will convert to financial tailwinds for the...
View ArticleTimber Pharmaceuticals' candidate for rare skin disorder flunks all endpoints...
Dermatology biotech Timber Pharmaceuticals’ Phase 3 trial investigating its treatment in a rare inherited skin disorder missed all primary and secondary endpoints, the company announced Wednesday. In...
View Article